A team of Dartmouth researchers has found that mothers who have developed antibodies against the herpes simplex virus (HSV-1) can pass these antibodies to the nervous systems of their infants, protecting them from acquiring the virus.
Thanks to a collaboration between the pharmaceutical company MedImmune and Geisel structural biologist Jason McLellan, PhD, a long-awaited vaccine to protect infants from RSV may soon become a reality. Their findings are featured as this month’s cover story in the journal Science Translational Medicine.
Geisel researchers Peter F. Wright and Alka Dev, who work with the Dartmouth-Haiti Partnership, were announced as winners of the Children’s Prize Foundation’s (CPF) 4th annual Children’s Prize.
Researchers at the Geisel School of Medicine and Dartmouth-Hitchcock health system have been awarded up to $42 million by the National Institutes of Health to investigate environmental influences on child health.
Ask Suzanne Boulter MED’66 what she has been doing since she retired from clinical practice in 2010, and you won’t hear about a life of leisure. She is currently working on a nationwide American Academy of Pediatrics program called “Brush, Book, and Bed.”
In a new study scheduled for publication in The Journal of Pediatrics, Dartmouth researchers found that the more children watched television channels that aired ads for children’s fast food meals, the more frequently their families visited those fast food restaurants.
A new Dartmouth study found that admission rates to neonatal intensive care units (NICUs) are increasing for newborns of all weights. In effect, NICUs are increasingly caring for normal, or near normal, birth weight and term infants. The study, recently published online by JAMA Pediatrics, raises questions about possible overuse of this highly specialized and expensive care for some newborns.
A team of Geisel faculty, students, and pediatric staff at Children’s Hospital at Dartmouth-Hitchcock received a Clinical Care Innovation Challenge Award from the Association of American Medical Colleges for creating a new model of care for in utero opioid-exposed and Neonatal Abstinence Syndrome-affected newborns.
Seattle Times – Quotes David Roberts, professor of surgery and neurology, on news that Seattle Children’s Hospital will be testing a new dye derived from scorpion venom that lights up cancer cells so surgeons can see — and remove — deadly brain tumors. Roberts and other colleagues have also been testing a similar drug compound, 5-aminolevulinic acid (5-ALA), which targets glial tumors.
A three-year, $800,000 grant from the Anthem Foundation to The Dartmouth Institute for Health Policy & Clinical Practice will fund the first comprehensive, nationwide study of neonatal intensive care.